[1]于洋杰 谢坤 施海明.血管生成素样蛋白3抑制剂研究进展[J].心血管病学进展,2021,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.013]
　YU Yangjie,XIE Kun,SHI Haiming.Angiopoietin-like Protein 3 Inhibitors[J].Advances in Cardiovascular Diseases,2021,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.013]
点击复制

血管生成素样蛋白3抑制剂研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年6期
页码:
530
栏目:
综述
出版日期:
2021-06-25

文章信息/Info

Title:
Angiopoietin-like Protein 3 Inhibitors
作者:
于洋杰 谢坤 施海明
(复旦大学附属华山医院心内科,上海200040)
Author(s):
YU Yangjie;  XIE Kun;  SHI Haiming
(Department Of CardiologyHuashan Hospital of Fudan UniversityShanghai 200040 China)
关键词:
血管生成素样蛋白3;  低密度脂蛋白胆固醇;  动脉粥样硬化;  心血管疾病
Keywords:
Angiopoietin-like protein 3;  Low-density lipoprotein cholesterol;  Atherosclerosis;  Cardiovascular disease
DOI:
10.16806/j.cnki.issn.1004-3934.2021.06.013
摘要:
家族性高胆固醇血症是一种常染色体显性遗传病，传统调脂药物对于这类患者的效果非常不理想。血管生成素样蛋白3单克隆抗体的出现为这些患者带来了希望。本文综述血管生成素样蛋白3相关研究进展。
Abstract:
Familial hypercholesterolemia is an autosomal dominant hereditary disease. Traditional lipid regulating drugs have less effect on these patients. The appearance of monoclonal antibody against angiopoietin -like protein 3 brings hope to these patients. In this review, we will summarize the most recent studies of angiopoietin-like protein 3

参考文献/References:

[1] Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.

[2] Ray KK ,Bays HE,Catapano AL,et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol[J]. N Engl J Med,2019,380(11):1022-1032.

[3] Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol[J]. N Engl J Med,2020:382(16):1507-1519.

[4] Li JJ,Li S,Zhu CG,et al. Familial hypercholesterolemia phenotype in Chinese patients undergoing coronary angiography[J]. Arterioscler Thromb Vasc Biol,2017,37(3):570-579.

[5] Cuchel M ,Bruckert E,Ginsberg HN,et al. Homozygous familial hypercholesterolaemia:new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society[J]. Eur Heart J,2014,35(32):2146-2157.

[6] Lee SH. Update on familial hypercholesterolemia:diagnosis,cardiovascular risk,and novel therapeutics[J]. Endocrinol Metab (Seoul),2017,32(1):36-40.

[7] Grundy SM ,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:Executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation,2019,139(25):e1046-e1081.

[8] Conklin D ,Gilbertson D,Taft DW,et al. Identification of a mammalian angiopoietin-related protein expressed specifically in liver[J]. Genomics,1999,62(3):477-482.

[9] Yoshida K ,Shimizugawa T,Ono M,et al. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase[J]. J Lipid Res,2002,43(11):1770-1772.

[10] Musunuru K,Pirruccello JP,Do R,et al. Exome sequencing,ANGPTL3 mutations,and familial combined hypolipidemia[J]. N Engl J Med,2010,363(23):2220-2227.

[11] Minicocci I,Montali A,Robciuc MR,et al. Mutations in the ANGPTL3 gene and familial combined hypolipidemia:a clinical and biochemical characterization[J]. J Clin Endocrinol Metab,2012,97(7):E1266-E1275.

[12] Arca M,Minicocci I,Maranghi M. The angiopoietin-like protein 3:a hepatokine with expanding role in metabolism[J]. Curr Opin Lipidol,2013,24(4):313-320.

[13] 王静巧，王双双，王建安，等. 血管生成素样蛋白3与脂质代谢及动脉粥样硬化的关系[J]. 中国细胞生物学学报,2019,41(5):985-991.

[14] Pisciotta L,Favari E,Magnolo L,et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3[J]. Circ Cardiovasc Genet,2012,5(1):42-50.

[15] Wang Y,Gusarova V,Banfi S,et al. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion[J]. J Lipid Res,2015,56(7):1296-1307.

[16] Adam RC,Mintah IJ,Alexa-Braun CA,et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance[J]. J Lipid Res,2020,61(9):1271-1286.

[17] Lupo MG,Ferri N. Angiopoietin-like 3 (ANGPTL3) and atherosclerosis:lipid and non-lipid related effects[J]. J Cardiovasc Dev Dis,2018,5(3):39.

[18] Chadwick A C,Evitt N H,Lv W,et al. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3[J]. Circulation,2018,137(9):975-977.

[19] Gusarova V,Alexa CA,Wang Y,et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys[J]. J Lipid Res,2015,56(7):1308-1317.

[20] Dewey FE,Gusarova V,Dunbar RL,et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease[J]. N Engl J Med,2017,377(3):211-221.

[21] Gaudet D,Gipe DA,Pordy R,et al. ANGPTL3 Inhibition in homozygous familial hypercholesterolemia[J]. N Engl J Med,2017,377(3):296-297.

[22] Raal FJ,Rosenson RS,Reeskamp LF,et al. Evinacumab for homozygous familial hypercholesterolemia[J]. N Engl J Med,2020,383(8):711-720.

[23] Graham MJ,Lee RG,Brandt TA,et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides[J]. N Engl J Med,2017,377(3):222-232.

[24] Gaudet D,Karwatowska-Prokopczuk E,Baum S J,et al. Vupanorsen,an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA,lowers triglycerides and atherogenic lipoproteins in patients with diabetes,hepatic steatosis,and hypertriglyceridaemia[J]. Eur Heart J,2020:41(40):3936-3945.

[25] Xu YX,Redon V,Yu H,et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol[J]. Atherosclerosis,2018,268:196-206.

[26] Cannon CP,Blazing MA,Giugliano RP,et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med,2015,372(25):2387-2397.

[27] Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.

[28] Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107.

[29] Hirayama K,Ota T,Harada K,et al. Impact of paradoxical decrease in high-density lipoprotein cholesterol levels after statin therapy on major adverse cardiovascular events in patients with stable angina pectoris[J]. Clin Ther,2017,39(2):279-287.

[30] Park JS,Cha KS,Lee HW,et al. Predictive and protective role of high-density lipoprotein cholesterol in acute myocardial infarction[J]. Cardiol J,2019,26(2):176-185.

相似文献/References:

[1]苏婷,张盼晓,王志禄.前蛋白转化酶枯草溶菌素9抑制剂: 阿利库单抗的研究进展[J].心血管病学进展,2016,(1):78.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.020]
　SU Ting,ZHANG Panxiao,WANG Zhilu.Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Research Advances in Alirocumab[J].Advances in Cardiovascular Diseases,2016,(6):78.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.020]
[2]于洋杰 谢坤 高秀芳 施海明 李勇.非高密度脂蛋白胆固醇可以替代低密度脂蛋白胆固醇吗？[J].心血管病学进展,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
　YU Yangjie,XIE Kun,GAO Xiufang,et al.Can LDL-C be Replaced by non-HDL-C[J].Advances in Cardiovascular Diseases,2021,(6):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]

备注/Memo

备注/Memo:
通讯作者：施海明，Email：Shihm@medmail.com.cn
更新日期/Last Update: 2021-07-23